Announcements Trials

Browse Landscape

Phase

Phase 1 2 Phase EARLY_PHASE1 1 Phase 2 1

Status

Active not recruiting 4 Terminated 3 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Histiocytic Neoplasms 1

Interventions

pembrolizumab 223 Carboplatin 222 Specimen Handling 194 Cisplatin 192 Magnetic Resonance Spectroscopy 165 Radiotherapy 153 Bevacizumab 143 Gemcitabine 136 Cyclophosphamide 135 Drug Therapy 119 Capecitabine 118 Paclitaxel 116 Oxaliplatin 111 Nivolumab 105 Biopsy 104 venetoclax 103 tislelizumab 83 Rituximab 83 durvalumab 82 toripalimab 78 Fluorouracil 73 Etoposide 72 Docetaxel 69 Dexamethasone 69 sintilimab 67 Pemetrexed 67 atezolizumab 65 Radiosurgery 65 Azacitidine 63 130-nm albumin-bound paclitaxel 62

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Recruiting × ulixertinib × Clear all

NCT06411821 2025-12-15

Ulixertinib in People With Histiocytic Neoplasms

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting

Histiocytic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡